The University of Kansas Cancer Center

https://www.kucancercenter.org/

 

ASH Update on Moderate-Intensity Chemo for AML: What Are the Remission Rates & OS of AZA/VEN, and LDAC/VEN? Does OS Improve With VEN + Decitabine for TP53 Mutation in AML, and What Are the New Potential Agents?

6 views
March 5, 2021
0 Comments
Login to view comments. Click here to Login
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases